149 related articles for article (PubMed ID: 11249645)
1. Technology evaluation: MFG-IRAP, University of Pittsburgh.
Baragi VM
Curr Opin Mol Ther; 2000 Apr; 2(2):216-20. PubMed ID: 11249645
[TBL] [Abstract][Full Text] [Related]
2. MFG-IRAP University of Pittsburgh.
Baragi VM
Curr Opin Investig Drugs; 2000 Oct; 1(2):194-8. PubMed ID: 11249573
[TBL] [Abstract][Full Text] [Related]
3. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10.
Zhang X; Mao Z; Yu C
J Orthop Res; 2004 Jul; 22(4):742-50. PubMed ID: 15183429
[TBL] [Abstract][Full Text] [Related]
4. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy.
Otani K; Nita I; Macaulay W; Georgescu HI; Robbins PD; Evans CH
J Immunol; 1996 May; 156(9):3558-62. PubMed ID: 8617986
[TBL] [Abstract][Full Text] [Related]
5. MFG-IRAP University of Pittsburgh.
Baragi VM
IDrugs; 1998 Jul; 1(3):344-9. PubMed ID: 18465559
[TBL] [Abstract][Full Text] [Related]
6. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium.
Hung GL; Galea-Lauri J; Mueller GM; Georgescu HI; Larkin LA; Suchanek MK; Tindal MH; Robbins PD; Evans CH
Gene Ther; 1994 Jan; 1(1):64-9. PubMed ID: 7584062
[TBL] [Abstract][Full Text] [Related]
7. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis.
Oligino T; Ghivizzani S; Wolfe D; Lechman E; Krisky D; Mi Z; Evans C; Robbins P; Glorioso J
Gene Ther; 1999 Oct; 6(10):1713-20. PubMed ID: 10516720
[TBL] [Abstract][Full Text] [Related]
8. Osteoarthritis gene therapy.
Evans CH; Gouze JN; Gouze E; Robbins PD; Ghivizzani SC
Gene Ther; 2004 Feb; 11(4):379-89. PubMed ID: 14724685
[TBL] [Abstract][Full Text] [Related]
9. The interleukin-1 receptor antagonist and its delivery by gene transfer.
Evans CH; Robbins PD
Receptor; 1994; 4(1):9-15. PubMed ID: 8038709
[TBL] [Abstract][Full Text] [Related]
10. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene.
Frisbie DD; Ghivizzani SC; Robbins PD; Evans CH; McIlwraith CW
Gene Ther; 2002 Jan; 9(1):12-20. PubMed ID: 11850718
[TBL] [Abstract][Full Text] [Related]
11. Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer.
Wang HJ; Yu CL; Kishi H; Motoki K; Mao ZB; Muraguchi A
Chin Med J (Engl); 2006 Aug; 119(16):1365-73. PubMed ID: 16934183
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
Hur W; Cho ML; Yoon SK; Kim SY; Ju JH; Jhun JY; Heo SB; Moon YM; Min SY; Park SH; Kim HY
Immunol Lett; 2006 Aug; 106(2):154-62. PubMed ID: 16793145
[TBL] [Abstract][Full Text] [Related]
13. The promise of a new clinical trial--intra-articular IL-1 receptor antagonist.
Evans CH; Robbins PD
Proc Assoc Am Physicians; 1996 Jan; 108(1):1-5. PubMed ID: 8834057
[TBL] [Abstract][Full Text] [Related]
14. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
Mease PJ; Hobbs K; Chalmers A; El-Gabalawy H; Bookman A; Keystone E; Furst DE; Anklesaria P; Heald AE
Ann Rheum Dis; 2009 Aug; 68(8):1247-54. PubMed ID: 18678578
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
Nuki G; Bresnihan B; Bear MB; McCabe D;
Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
[TBL] [Abstract][Full Text] [Related]
16. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
[TBL] [Abstract][Full Text] [Related]
17. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
Verbsky JW; White AJ
J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
[TBL] [Abstract][Full Text] [Related]
18. Arthritis: is the cure in your genes?
Herndon JH; Robbins PD; Evans CH
J Bone Joint Surg Am; 1999 Feb; 81(2):152-7. PubMed ID: 10073578
[No Abstract] [Full Text] [Related]
19. Interleukin-1 receptor antagonist gene therapy for arthritis.
Krishnan BR
Curr Opin Mol Ther; 1999 Aug; 1(4):454-7. PubMed ID: 11713759
[TBL] [Abstract][Full Text] [Related]
20. C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to cytomegalovirus-regulated expression of the same transgene.
Bakker AC; van de Loo FA; Joosten LA; Arntz OJ; Varley AW; Munford RS; van den Berg WB
Arthritis Rheum; 2002 Jun; 46(6):1661-70. PubMed ID: 12115199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
